Roth Capital Doubles Down on Cybin After DMT Acquisition

Earlier this week we reported on Cybin acquiring a DMT Clinical Study from Entheon Biomedical. The study is the largest Phase 1 DMT trial to date and should greatly accelerate Cybin’s CYB-004 DMT program.

And it seems like the financial world agrees on the potential benefits of this move, as Roth Capital has reiterated its Buy rating and bullish price target for Cybin. Based on this acquisition and strengthening of its DMT program, Roth has kept its $10 target, a sign of faith in the company’s programs especially considering the difficult market conditions.

See below for a brief look at Roth’s report and stay tuned to Microdose for a full interview with Roth Capital analyst Elemer Piros.

Interested in more like this? See MindMed Receives 700% Price Target From Roth Capital

Order Lasix Online Pharmacy